DiaSorin is an Italian specialty IVD company with revenues of approximately $1.5 billion in 2025, specializing in immunoassay for specialty testing, molecular diagnostics, and clinical chemistry. DiaSorin is the global leader in vitamin D testing — a dominant market position in a high-volume specialty immunoassay segment — and holds strong positions in infectious disease serology, bone metabolism, and endocrinology testing. The company's 2021 acquisition of Luminex significantly expanded its molecular diagnostics portfolio, adding multiplex syndromic testing and flow cytometry-based immunoassay platforms. DiaSorin's LIAISON platform is deployed in immunoassay laboratories globally.
92 countries — 38 European, 18 Asia-Pacific, 22 Latin American, 11 Middle Eastern, and 3 North American countries.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Strategic Directions — Specialty Immunoassay Leadership, Luminex Integration, and Molecular Expansion Through 2030
• Financial Performance — Revenue, Revenue by Segment, Revenue by Geography, EBITDA, and R&D 2023-2025
• SWOT Analysis — Competitive Advantages, Structural Vulnerabilities, Opportunities, and Risks
• Technological Know-How — LIAISON Platform, Luminex xMAP, Specialty Immunoassay, and IP
• Latest Products and Services — New Specialty Assays, Luminex Integration, and Pipeline
• M&A — Luminex Integration Progress, Joint Ventures, and Partnerships 2023-2025
• Marketing Tactics — Specialty Testing Market Strategy and Channel Positioning
• Organization and Management — Leadership, Structure, and Workforce
'
Table of Contents
1. Executive Summary
- Key findings and strategic implications
- Most significant developments 2024-2025
- Strategic recommendations
2. Strategic Directions
- Portfolio strategy and capital allocation priorities
- Technology investment focus areas
- Geographic expansion and market development
- Growth priorities through 2030
3. Financial Performance
- Revenue and revenue growth 2023-2025
- Revenue by segment 2023-2025
- Revenue by geography 2023-2025
- Operating income, margins, and EBITDA 2023-2025
- R&D investment 2023-2025
4. SWOT Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
5. Technological Know-How
- Core technology capabilities and IP portfolio
- AI and digital diagnostics investments
- Key platform systems and technology milestones
6. Latest Products and Services
- Recent product and platform launches 2023-2025
- Key analyzer and reagent portfolio
- Innovation pipeline and development programs
7. M&A
- Acquisitions, divestitures, and partnerships 2023-2025
8. Marketing Tactics
- Segment and channel positioning
- Reagent rental and placement strategy
- Key account and GPO strategy
9. Organization and Management
- Leadership and executive team
- Organizational structure and key changes
- Workforce size and developments
10. Appendix
- Research methodology
- Abbreviations and definitions
- List of tables and figures
List of Tables
Table 1. DiaSorin — Key Financial Metrics Summary 2023-2025
Table 2. DiaSorin — Revenue by Segment 2023-2025
Table 3. DiaSorin — Revenue by Geography 2023-2025
Table 4. DiaSorin — R&D Investment 2023-2025
Table 5. DiaSorin — SWOT Analysis
Table 6. DiaSorin — Core Technology Capabilities and Key Platforms
Table 7. DiaSorin — Key Analyzers and Reagent Portfolio
Table 8. DiaSorin — M&A Activity Summary 2023-2025
Table 9. DiaSorin — Key Management and Leadership
Table 10. DiaSorin — Strategic Priorities 2025-2030
